JNJ Growth Product Cohort Replaces Lost Sales with $2.4 Billion in New Ones

Johnson & Johnson's (JNJ) recent quarterly earnings report provided some reassuring news for investors. The company's growth product cohort saw a significant increase in sales, more than making up for the losses incurred from the decline of Stelara. In fact, JNJ was able to replace $913 million in lost sales with an impressive $2.4 billion in new ones.

However, it's worth noting that the company only retained less than half of these new sales, which raises some concerns about its ability to sustain growth. Despite this, JNJ's valuation remains above historical averages, already pricing in competent execution. To see further upside, investors will need clear evidence of accelerating growth in both Innovative Medicine and MedTech.

One key risk area for JNJ is the potential erosion of its drug portfolio due to biosimilar competition. Additionally, the delayed recovery of MedTech and unresolved talc litigation could impact cash flow and rating trajectory. Nevertheless, free cash flow and profitability remain strong, with dividends and buybacks exceeding free cash flow.